Jim Cramer threw a curveball on Pfizer’s stock during a recent caller interaction, suggesting a wait-and-see approach ...

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain ...

Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Here are five high-yield dividend stocks that offer passive income and solid entry points that investors can buy and forget ...

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Thursday it has begun discussions with the U.S. government to launch ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...